Eli Lilly’s latest weight-loss drug relieved ache in sufferers with knee osteoarthritis
Published:
One of Eli Lilly’s most promising new obesity drugs helped patients lose about 28.7% of their body weight while also reducing pain associated with knee osteoarthritis.
The drug giant’s
LLY stock was up about 1% in premarket trading Thursday after announcing the Phase 3 data for retatrutide, a GIP, GLP-1 and glucagon triple hormone receptor agonist that Lilly refers to as “triple G.”